Celgene Corporation Buyback
OLI recorded this information on 2/14/2018
Celgene Corporation (NASDAQ:CELG) today announced the Company's Board of Directors authorized the repurchase of an additional $5 billion of the Company's common stock. This open-ended program is effective immediately. Purchases may be made in the open market or in privately negotiated transactions from time to time, as determined by Celgene's management and in accordance with the requirements of the Securities and Exchange Commission.
Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. Co.'s products are sold primarily to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics and government agencies. Co. manufactures products in the U.S. and Puerto Rico and has manufacturing operations in several foreign countries. Co. has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. Co.'s pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.
Open the CELG Page at The Online Investor »
Free CELG Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite